Research and development of comprehensive tumor diagnostic and therapeutic agents using radioactive metals

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K08102
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52040:Radiological sciences-related
• Research Institution: Kanazawa University
• Principal Investigator: Kitamura Yoji 金沢大学, 疾患モデル総合研究センター, 准教授 (10368483)
• Co-Investigator(Kenkyū-buntansha): 小川 数馬 金沢大学, 新学術創成研究機構, 教授 (30347471)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 放射性医薬品 / ポルフィリン / 金属 / 錯体 / 腫瘍

Outline of Final Research Achievements

The purpose of this study is to develop a new "radiometal-obrominated porphyrin complex" and to clarify its potential application as a tumor diagnostic and therapeutic agent. 111In-OBTCPP, which was labeled with 111In, was injected to tumor-bearing mice implanted with lung cancer. SPECT-CT imaging was conducted 24 hours after administration. As a result, no accumulation of radioactivity in bone was observed, but there was almost no accumulation in the tumors. Although it was confirmed that 111In-OBTCPP does not occur demetalization after administration into mice, the accumulation of radioactivity in tumors should be investigated again using tumor-bearing mice with well-grown tumors.

Free Research Field

放射性医薬品

Academic Significance and Societal Importance of the Research Achievements

本研究の学術的に新規な点は、ポルフィリンの中でも、特に、他のポルフィリン類に比べ、金属との結合の速い、八臭素化ポルフィリン誘導体に着目している点である。八臭素化ポルフィリン誘導体であるOBTCPPが短時間での111In標識が可能であり、小動物SPECT-CTで担癌マウスの撮像を行えた点は、今後のポルフィリン誘導体を利用した腫瘍診断・治療薬剤の開発における基礎的知見となり得ると考えられる。